Last reviewed · How we verify
bacteriophage preparation
bacteriophage preparation is a Small molecule drug developed by Nterica Bio inc. It is currently in Phase 1 development. Also known as: EcoActive.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | bacteriophage preparation |
|---|---|
| Also known as | EcoActive |
| Sponsor | Nterica Bio inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study (NA)
- Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis (PHASE1)
- Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis (PHASE1, PHASE2)
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease (PHASE1, PHASE2)
- Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection (PHASE1, PHASE2)
- Use of Phage Therapy for Treatment of a Periprosthetic Joint Infection (PHASE1)
- Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects (PHASE1, PHASE2)
- Photodegraded Edible Food Dyes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bacteriophage preparation CI brief — competitive landscape report
- bacteriophage preparation updates RSS · CI watch RSS
- Nterica Bio inc portfolio CI
Frequently asked questions about bacteriophage preparation
What is bacteriophage preparation?
Who makes bacteriophage preparation?
Is bacteriophage preparation also known as anything else?
What development phase is bacteriophage preparation in?
Related
- Manufacturer: Nterica Bio inc — full pipeline
- Also known as: EcoActive
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing